Company
NephroDI Therapeutics
NephroDI Therapeutics is a pharmaceutical company focusing on concentration disorders of the kidney.
- Status
- Operatingas of 2026-09-20
- Headquarters
- Seattle, Washington, United States
Claim, correct or request removal
Record updated 28 September 2026
About
NephroDI is initially developing an oral drug to treat Nephrogenic Diabetes Insipidus (NDI) in children, a pediatric orphan disease.
Funding snapshot
- Total raised
- $3.6MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Series A2024-06-20
Funding rounds
- Series A
- 2024-06-20
- Round, 2024
- $2M2024-06-11, SEC form D sold, 2 investors
- Round, 2021
- $1.6M2021-02-11, SEC form D sold, 1 investor
Products
- Other
- NDI-5001
Loading relationship preview